论文部分内容阅读
用逆转录——多聚酶链反应（ＲＴ－ＰＣＲ）技术检测了５２例急性白血病（ＡＬ）患者与８例正常人临床标本多药耐药基因（ＭＤＲ１）的表达，并观察患者对化疗药物的反应。结果表明：初诊未化疗者ＭＤＲ１阳性表达率为１５．６３％，提示ＭＤＲ的原发性；复发和未缓解者ＭＤＲ１表达率为７１．４３％，显著高于初治者。ＭＤＲ１阳性表达组完全缓解率为１３．３３％，显著低于ＭＤＲ１阴性表达组（＞７７．４２％）。认为该项检测对指导临床医师选择制定化疗方案、判断预后、提高疗效有重要意义。
The reverse transcription-polymerase chain reaction (RT-PCR) technique was used to detect the expression of multidrug resistance gene (MDR1) in 52 patients with acute leukemia (AL) and 8 normal subjects, and to observe the response of patients to chemotherapy drugs. . The results showed that the positive expression rate of MDR1 was 15.63% in the newly diagnosed non-chemotherapy patients, suggesting that the MDR was primary; the rate of MDR1 expression in relapsed and non-remitted patients was 71.43%, which was significantly higher than that of the newly diagnosed patients. The complete response rate in the MDR1 positive expression group was 13.33%, which was significantly lower than the MDR1 negative expression group (>77.42%). It is believed that this test has important implications for guiding clinicians in selecting chemotherapy plans, predicting prognosis, and improving efficacy.